Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic py<sub>2</sub>-macrodipa for <sup>225</sup>Ac/<sup>89</sup>Zr Paired Theranostics.

Inorganic chemistry·2026
Same author

Correction to "Size-Adaptive Macrocyclic Coordination of <sup>203</sup>Pb, <sup>207</sup>Bi, and <sup>133</sup>Ba by py-Macrodipa and py<sub>2</sub>-Macrodipa".

Inorganic chemistry·2026
Same author

Photoreactivity of Ru<sup>2+</sup> Polypyridyl Complexes Bearing the H<sub>2</sub>S-Releasing Compound GYY4137.

Inorganic chemistry·2026
Same author

Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors.

Radiation (Multidisciplinary Digital Publishing Institute)·2026
Same author

Picolinate-based acyclic ligand for rare earth element extraction and separation.

Chemical science·2026
Same author

Size-Adaptive Macrocyclic Coordination of <sup>203</sup>Pb, <sup>207</sup>Bi, and <sup>133</sup>Ba by py-Macrodipa and py<sub>2</sub>-Macrodipa.

Inorganic chemistry·2026

Related Experiment Video

Updated: May 10, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Monofunctional and higher-valent platinum anticancer agents.

Timothy C Johnstone1, Justin J Wilson, Stephen J Lippard

  • 1Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.

Inorganic Chemistry
|June 7, 2013
PubMed
Summary

Researchers are developing novel platinum compounds and delivery systems to overcome resistance and toxicity in cancer treatment. This includes exploring non-traditional platinum structures and advanced nanoconstructs for improved efficacy.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Medicinal inorganic chemistry
  • Cancer therapeutics
  • Drug delivery systems

Background:

  • Platinum compounds like cisplatin are vital anticancer agents.
  • Existing platinum drugs face challenges of toxicity and drug resistance.
  • New strategies are essential to enhance platinum-based cancer therapy.

Purpose of the Study:

  • To explore novel platinum(II) and platinum(IV) compounds for cancer treatment.
  • To investigate advanced drug-delivery strategies for platinum-based therapies.
  • To present recent laboratory developments and historical context of platinum compound research.

Main Methods:

  • Synthesis and testing of monofunctional platinum(II) complexes.
  • Evaluation of platinum(IV) prodrugs.
  • Development of nanoconstructs for in vivo drug delivery.

Main Results:

  • Identification of non-traditional platinum compounds with potential anticancer activity.
  • Demonstration of specialized drug-delivery strategies to improve efficacy.
  • Advancement in the design of platinum-based nanomedicines.

Conclusions:

  • Novel platinum compounds and delivery systems offer promising alternatives to overcome current limitations.
  • Continued research into "non-traditional" platinum agents and nanoconstructs is crucial for future cancer therapies.
  • The study highlights the evolution of platinum-based drug development and future directions.